Search Results

Peter Banks, Scientific Director at BioTek Instruments! Learn about his career today!

December 2021 "Meet Peter McNamara, Ph.D., Tectonic’s SVP, Head of Research. Peter joined Tectonic to help chart new territory in GPCR science. We’re glad to have Peter's dedication, experience, and passion in building innovative therapeutics."

Your scientific thinking built the foundation, but leadership is what scales it. The Invisible Obstacle   👉 Brilliant science. Stalled progress. It’s a pattern we see far too often in early-stage biotech operations and startups. The experiments work. The data looks promising. But decisions lag, the team spins, and investors get nervous. Science isn’t the problem; scientific thinking is. What makes you excel in the lab can quietly sabotage your leadership in the boardroom. 👉 Scientific thinking  rewards depth, rigor, and precision. But in a startup, those same instincts to analyze deeply, minimize error, and delay action until “enough” data is in can kill momentum . 👉 Most founders don’t even realize they’re still running their company like an academic research group. They explain instead of deciding. They analyze instead of acting.   ✅  This post explores how scientific thinking can become a leadership liability and what mindset shifts are needed to evolve from research reflexes to CEO decisions.   ✅  You don’t need to abandon your scientific instincts. But you do need to adapt them if you want your startup to scale .     The 3 Golden Rules of Scientific Thinking — and Why They Break Down in Biotech Operations Leadership   👉 Scientific thinking trains you to be precise, methodical, and skeptical. These instincts are critical in the lab, but they often undermine leadership when blindly applied in a startup . Let’s unpack the three core “rules” most scientific founders unconsciously carry into their companies:   1️⃣ “Only act when the data is solid.” In research, acting on incomplete or shaky data can destroy your credibility. In startups, waiting too long for certainty can destroy your momentum . 👉 Biotech founders often delay critical business moves, hiring, BD outreach, or funding decisions, because the data isn't “mature enough.” But in business, decisions must be made under uncertainty . Clarity doesn’t precede action; it follows it.   2️⃣ “Eliminate error at all costs” Labs are built around error reduction. You control variables. You minimize noise. But startups are inherently noisy. Trying to eliminate all risk leads to overengineering and stagnation . 👉 Instead of shipping early and iterating, many scientific founders keep refining decks, processes, and team structures until they feel bulletproof. But by then, the window of opportunity has often closed.   3️⃣ “Deep analysis leads to better answers” Scientific training favors deep thinking. More analysis = better outcomes. But in leadership, depth without speed equals paralysis . 👉 Startups don’t reward depth alone; they reward direction and decisiveness . Over-analysis becomes a form of avoidance. And while you're analyzing, someone else is executing.   👉 Bottom line:  Scientific thinking is invaluable, but only when it’s reframed for the role you’re actually in. ✅ You’re not optimizing experiments anymore. You’re steering a company.     Startups Play by Different Rules — and Most Scientific Founders Miss That   A research lab is designed for precision. A startup is designed for progress. And that difference changes everything. 👉 Scientific thinking values thoroughness, error reduction, and complete data before action.  But in the startup environment, these instincts can quickly become liabilities. You rarely have perfect data. 👉 You can’t eliminate every variable. And waiting too long often means missing the moment. Startups demand something different: ✅ Clarity of direction even when the picture is incomplete. The ability to decide when no option is risk-free. The discipline to align a team without all the answers. Founders who keep operating like researchers often create internal confusion. They revise instead of committing. They analyze instead of align. They aim for perfect clarity, and in doing so, they delay momentum, erode trust, and weaken execution. ✅ Scientific thinking can make you cautious when your company needs decisiveness. Unless you update the way you lead, your startup will struggle to translate insight into impact.   Leadership isn’t in your lab notebook; it’s in how you decide     How to Know If You're Still Leading Like a Scientist   👉 Leadership isn’t a title. It’s a way of thinking. And if your thinking is still shaped by academic norms, your startup will keep running like a lab, not a company. 👉Scientific thinking is precise. Leadership thinking is directional. The transition between the two isn’t automatic, even for the most capable founders. It requires conscious shifts in how you process uncertainty, how you frame decisions, and how you lead people through ambiguity. Here are three questions to help you check in with yourself: 1️⃣ Do you delay or dilute decisions while waiting for more clarity? Real leadership often means choosing without all the answers. If you find yourself looping decisions or delegating them upward, you might be leaning on scientific habits to avoid risk.   2️⃣ Do you overvalue internal logic over external action? It’s tempting to refine the deck, rework the roadmap, or re-analyze the market. But leadership is outward-facing. It’s about choosing direction, enabling others to move, and owning tradeoffs with imperfect inputs.   3️⃣ Do you explain more than you align? Explaining a model is not the same as rallying a team. When your communication centers on logic and detail instead of clarity and momentum, your team stays in wait mode, and execution stalls.   ✅ The shift from scientist to CEO  is not about abandoning your expertise. It’s about realizing that your value now lies in decisions, not just in depth.     Strategic Takeaway   👉 Scientific thinking will always be your strength, but it must be reshaped to serve your new role. 👉 As a biotech founder, your impact no longer comes from precision alone, but from your ability to lead through uncertainty, prioritize progress over perfection, and turn insight into execution. ✅  Leadership is not the opposite of science. It’s what gives it direction.   Ready to Break Your Bottlenecks?          If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

Kozielewicz, et al. for their study on Frizzleds act as dynamic pharmacological entities Marina Casiraghi, Robert J Lefkowitz, Peter Gmeiner, Brian K Kobilka et al. for their investigation on Molecular insights into We define a developing country based on World Bank Classifications for its 2024 fiscal year. Receptor in Complex with CGRP and Gs Protein Industry News Monash University retains its N° 2 global ranking

and antihistamines: A clinical trial is needed Jillian G Baker ,  Erica K Sloan ,   Kevin Pfleger ,  Peter at two distinct sites of a human bitter taste GPCR Lior Peri ,  Donna Matzov ,  Dominic R Huxley ,   Peter Gmeiner ,  Peter J McCormick ,  Dorothee Weikert ,  Masha Y Niv ,  Moran Shalev-Benami , et al. platform to connect from anywhere in the world  And if you go for a Premium Membership , you'll not only back Georgios Skiniotis as Director of the New Center of Excellence for Structural Cell Biology Monash Scholars Ranked

Robert Lefkowitz on his 50 years at Duke. Congratulations. Dr. leukotriene G-protein coupled receptors Industry News Duke University Celebrates Nobel Prize Winner Robert Targets: Allosteric Function and Biased Signaling" at the DOT NEW October 2 - 3, 2023 | Celebrating Robert

G-Protein Coupled Receptors), today announced the promotion of Senior Vice President, Head of Research, Peter

Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business

Robert Lefkowitz Lab Postdoc Fellow - Dr. Robert Lefkowitz Lab Explore Dr. GPCR Ecosystem

Premium members can always go back and watch the recorded talks at any time. Robert Lefkowitz Lab NEW Postdoc Fellow - Dr. Robert Lefkowitz Lab Senior Research Specialist - Natural Sciences - Surgery Senior Scientist- Membrane

The company's co-founder, GPCR pioneer and Nobel laureate Robert Lefkowitz, M.D., has 50 years of experience

Welcome back to your weekly GPCR quest! his article Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter

Robert Lefkowitz Lab Postdoc Fellow - Dr. Robert Lefkowitz Lab Senior Research Specialist - Natural Sciences - Surgery Senior Scientist- Membrane

thrilled to announce that our co-founder Margaux Duchamp has been selected as a 30 under 30 Europe Forbes ranking

Robert Lefkowitz Lab Postdoc Fellow - Dr. Robert Lefkowitz Lab Senior Research Specialist - Natural Sciences - Surgery Senior Scientist- Membrane

Welcome back to your weekly GPCR quest! his article Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter Scientific Advisory Board GLP-1s like Ozempic are among the most important drug breakthroughs ever Goldman-backed

‘Define your own success’: Duke leaders talk success, failure at symposium honoring Nobel Laureate Robert

Robert J Lefkowitz. Join us tomorrow, July 21, in the Dr.

If you couldn't make it, no sweat – our premium members can always go back and watch the recorded talks Deadline September 27, 2023 GPCR Events, Meetings, and Webinars October 2 - 3, 2023 | Celebrating Robert

differentially report on GPCR-G protein coupling Samuel Liu, Preston Anderson, Sudarshan Rajagopal, Robert Terry Kenakin will conduct two back-to-back courses this fall. The two back-to-back courses are new and specially tailored to the Dr.

Robert Lefkowitz for their work on GPCRs: from radioligand binding to cellular signaling Dr. a resounding success; we have a waitlist for those eager to attend this course, which wil be coming back

Bryan Roth, Peter Gmeiner, and Thomas P. Sakmar this week. For Dr.

Robert J Lefkowitz and team's study 'GPCR signal transduction: β-arrestin activates ERK MAPK.' Dr.

consequences of spatial, temporal and ligand bias of G protein-coupled receptors Antonios Drakopoulos, Peter

discovery and sequencing of the beta-adrenergic receptor (βAR), the first GPCR to be identified by Robert

gap in cardiometabolic diseases GPCR Events, Meetings, and Webinars October 2 - 3, 2023 | Celebrating Robert

This week's highlight includes congrats to: Makaía M Papasergi-Scott, Peter Gmeiner, Brian K Kobilka,

Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 Crinetics Pharmaceuticals Appoints Robert

identify specificity-determining positions without prior knowledge of structure or sequence homology (Di Roberto Di Roberto, R. B., Chang, B., & Peisajovich, S. G. (2017).

relevant to GPCR-mediated signaling was the 2012 Nobel Prize in Chemistry to Brian Kent Kobilka and Robert Robert J.